Nothing Special   »   [go: up one dir, main page]

MX2022000779A - Anticuerpo monoclonal anti-vegf humanizado. - Google Patents

Anticuerpo monoclonal anti-vegf humanizado.

Info

Publication number
MX2022000779A
MX2022000779A MX2022000779A MX2022000779A MX2022000779A MX 2022000779 A MX2022000779 A MX 2022000779A MX 2022000779 A MX2022000779 A MX 2022000779A MX 2022000779 A MX2022000779 A MX 2022000779A MX 2022000779 A MX2022000779 A MX 2022000779A
Authority
MX
Mexico
Prior art keywords
vegf
antibody
monoclonal antibody
nucleic acid
acid sequence
Prior art date
Application number
MX2022000779A
Other languages
English (en)
Inventor
Xiao Zhang
Rui Wang
Liangzhi Xie
Chunyun Sun
Original Assignee
Sinocelltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinocelltech Ltd filed Critical Sinocelltech Ltd
Publication of MX2022000779A publication Critical patent/MX2022000779A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al campo de la inmunoterapia tumoral y se relaciona con un anticuerpo monoclonal humanizado que se une a VEGF. La presente invención describe secuencias de ácidos nucleicos (incluyendo las regiones variables de las cadenas pesada/ligera) que codifican los anticuerpos y vectores, composiciones farmacéuticas y kits que contienen las secuencias de ácidos nucleicos. El anticuerpo descrito en la presente invención puede unirse específicamente a VEGF con alta afinidad y bloquear la unión de VEGF en el receptor VEGFR2. Los anticuerpos también neutralizan el efecto proliferativo de la proteína VEGF165 y múltiples subtipos de VEGF sobre las células HUVEC y pueden utilizarse en el tratamiento clínico de tumores, incluidos, pero no limitados a: cáncer colorrectal.
MX2022000779A 2019-07-19 2020-07-17 Anticuerpo monoclonal anti-vegf humanizado. MX2022000779A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910657497 2019-07-19
PCT/CN2020/102622 WO2021013080A1 (zh) 2019-07-19 2020-07-17 人源化抗vegf单克隆抗体

Publications (1)

Publication Number Publication Date
MX2022000779A true MX2022000779A (es) 2022-02-14

Family

ID=74193255

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000779A MX2022000779A (es) 2019-07-19 2020-07-17 Anticuerpo monoclonal anti-vegf humanizado.

Country Status (10)

Country Link
US (1) US12060416B2 (es)
EP (1) EP4001306A4 (es)
JP (1) JP7352007B2 (es)
KR (1) KR20220071177A (es)
CN (1) CN114008075B (es)
AU (1) AU2020316498B2 (es)
BR (1) BR112022001017A2 (es)
CA (1) CA3147921C (es)
MX (1) MX2022000779A (es)
WO (1) WO2021013080A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7229419B2 (ja) * 2019-07-19 2023-02-27 神州細胞工程有限公司 ヒト化抗ｖｅｇｆ ｆａｂ抗体断片及びその使用
EP4292661A1 (en) * 2021-02-10 2023-12-20 Shanghai Jemincare Pharmaceuticals Co., Ltd. Anti-vegf antibody and use thereof
CN115850470B (zh) * 2022-12-12 2023-07-07 三门峡市眼科医院 Vegf抗体及其应用
CN117820474A (zh) * 2023-04-25 2024-04-05 南京贝思奥生物科技有限公司 改善眼部血管新生相关疾病的药物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR20200034817A (ko) 2003-05-30 2020-03-31 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
MX2012006072A (es) * 2009-11-30 2012-07-23 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
JP6706578B2 (ja) * 2013-12-30 2020-06-10 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Ｆａｂ免疫グロブリン及びその使用
CN108148136B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
CN108148133B (zh) * 2015-01-06 2020-04-24 珠海亿胜生物制药有限公司 抗vegf抗体
US10894083B2 (en) 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
US11007259B2 (en) * 2016-01-06 2021-05-18 Order-Made Medical Research Inc. High-affinity anti-VEGF antibody
JP7229419B2 (ja) * 2019-07-19 2023-02-27 神州細胞工程有限公司 ヒト化抗ｖｅｇｆ ｆａｂ抗体断片及びその使用

Also Published As

Publication number Publication date
US20220144930A1 (en) 2022-05-12
CA3147921A1 (en) 2021-01-28
US12060416B2 (en) 2024-08-13
BR112022001017A2 (pt) 2022-04-12
CN114008075A (zh) 2022-02-01
CA3147921C (en) 2023-02-21
WO2021013080A1 (zh) 2021-01-28
KR20220071177A (ko) 2022-05-31
JP7352007B2 (ja) 2023-09-27
JP2022542037A (ja) 2022-09-29
EP4001306A1 (en) 2022-05-25
EP4001306A4 (en) 2023-11-15
CN114008075B (zh) 2024-08-16
AU2020316498B2 (en) 2024-02-29
AU2020316498A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
MX2022000779A (es) Anticuerpo monoclonal anti-vegf humanizado.
ZA202002338B (en) Novel bispecific polypeptide complexes
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
EP4389226A3 (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
RU2022102446A (ru) Биспецифические связывающие белки и пути их применения
BR112012021941A2 (pt) Proteínas terapêuticas de ligação a dll4
IN2014MN02293A (es)
MX2018006072A (es) Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
JP2017149720A5 (es)
RU2013128444A (ru) Новые модуляторы и способы их применения
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
MX2010004910A (es) Anticuerpos monoclonales recombinantes y antigenos correspondientes para canceres colonico y pancreatico.
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
NZ586053A (en) Anti-vegf antibody compositions and methods
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
SG10201810507WA (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
JP2017506067A5 (es)
CA3148491A1 (en) Humanized anti-il17a antibody and use thereof
JP2013166763A5 (es)
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
MX2021007572A (es) Anticuerpo anti-pd-1 humanizado y uso del mismo.
PH12018502293B1 (en) Humanized anti-basigin antibodies and the use thereof
MX2022000174A (es) Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
RU2016129166A (ru) Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии